Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations

BRAF-V600 mutations occur in approximately 50% of patients with metastatic melanoma. Immune-checkpoint inhibitors and targeted therapies are both active as first-line treatments in these patients regardless of their mechanisms of action and toxicities. However, an upfront therapeutic strategy is sti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Adv Med Oncol
Egile Nagusiak: Giunta, Emilio Francesco, De Falco, Vincenzo, Napolitano, Stefania, Argenziano, Giuseppe, Brancaccio, Gabriella, Moscarella, Elvira, Ciardiello, Davide, Ciardiello, Fortunato, Troiani, Teresa
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2020
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307282/
https://ncbi.nlm.nih.gov/pubmed/32612709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920925219
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak